{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:36:25Z","timestamp":1792784185924,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009139","name":"German Center for Infection Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Swedish Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001729","name":"Swedish Foundation for Strategic Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001729","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003748","name":"Swedish Society for Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003748","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007232","name":"Cancer Research Foundations of Radiumhemmet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007232","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004063","name":"Knut and Alice Wallenberg Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"name":"\u00c5ke Wiberg\u2019s Foundation"},{"name":"Center for Innovative Medicine"},{"DOI":"10.13039\/501100004348","name":"Stockholm County Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.jhep.2018.05.004","type":"journal-article","created":{"date-parts":[[2018,6,29]],"date-time":"2018-06-29T08:55:26Z","timestamp":1530262526000},"page":"584-593","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":144,"title":["Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B"],"prefix":"10.1016","volume":"69","author":[{"given":"Franziska","family":"Rinker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine L.","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"H\u00f6ner zu Siederdissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Manns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke R.M.","family":"Kraft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiner","family":"Wedemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas K.","family":"Bj\u00f6rkstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Cornberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2018.05.004_b0005","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","article-title":"Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013","volume":"386","author":"Schweitzer","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2018.05.004_b0010","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.05.004_b0015","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/apt.13272","article-title":"Systematic review: cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B","volume":"42","author":"Chang","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2018.05.004_b0020","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/hep.28438","article-title":"Discontinuation of oral antivirals in chronic hepatitis B: a systematic review","volume":"63","author":"Papatheodoridis","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.05.004_b0025","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/infdis\/jiw412","article-title":"Viral and host responses after stopping long-term nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B","volume":"214","author":"Honer Zu Siederdissen","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2018.05.004_b0030","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jhep.2017.07.012","article-title":"Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study","volume":"67","author":"Berg","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.05.004_b0035","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1053\/j.gastro.2012.05.039","article-title":"Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir","volume":"143","author":"Hadziyannis","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2018.05.004_b0040","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/liv.13654","article-title":"Stopping long-term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg-negative chronic hepatitis B","volume":"38","author":"van Bommel","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2018.05.004_b0045","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1053\/j.gastro.2015.09.026","article-title":"Interferon-gamma and tumor necrosis factor-alpha produced by T cells reduce the HBV persistence form, cccDNA, without cytolysis","volume":"150","author":"Xia","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2018.05.004_b0050","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1128\/JVI.02844-06","article-title":"Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection","volume":"81","author":"Boni","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2018.05.004_b0055","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1053\/j.gastro.2012.07.014","article-title":"Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues","volume":"143","author":"Boni","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2018.05.004_b0060","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0168-8278(03)00292-7","article-title":"Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B","volume":"39","author":"Boni","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.05.004_b0065","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1002\/eji.201445369","article-title":"High-resolution determination of human immune cell signatures from fine-needle liver aspirates","volume":"45","author":"Hengst","year":"2015","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jhep.2018.05.004_b0070","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nm.4275","article-title":"Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B","volume":"23","author":"Fisicaro","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2018.05.004_b0075","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1128\/JVI.77.1.68-76.2003","article-title":"CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection","volume":"77","author":"Thimme","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2018.05.004_b0080","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/nm.3251","article-title":"Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells","volume":"19","author":"Rehermann","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2018.05.004_b0085","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1084\/jem.191.8.1269","article-title":"The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection","volume":"191","author":"Maini","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.jhep.2018.05.004_b0090","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S0016-5085(99)70289-1","article-title":"Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection","volume":"117","author":"Maini","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2018.05.004_b0095","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev.iy.13.040195.000333","article-title":"Hepatitis B virus immunopathogenesis","volume":"13","author":"Chisari","year":"1995","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jhep.2018.05.004_b0100","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0022-1759(02)00541-0","article-title":"Comparison of overlapping peptide sets for detection of antiviral CD8 and CD4 T cell responses","volume":"275","author":"Draenert","year":"2003","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.jhep.2018.05.004_b0105","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1084\/jem.20131333","article-title":"Dysfunctional CD8+ T cells in hepatitis B and C are characterized by a lack of antigen-specific T-bet induction","volume":"211","author":"Kurktschiev","year":"2014","journal-title":"J Exp Med"},{"key":"10.1016\/j.jhep.2018.05.004_b0110","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3389\/fimmu.2013.00475","article-title":"Clonal exhaustion as a mechanism to protect against severe immunopathology and death from an overwhelming CD8 T cell response","volume":"4","author":"Cornberg","year":"2013","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhep.2018.05.004_b0115","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/hep.23173","article-title":"Chronically inflamed livers up-regulate expression of inhibitory B7 family members","volume":"50","author":"Kassel","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.05.004_b0120","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiy097","article-title":"Increased NK cell function after cessation of long-term nucleos(t)ide analogue treatment in chronic hepatitis B associates with liver damage and HBsAg loss","author":"Zimmer","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2018.05.004_b0125","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jhep.2009.12.015","article-title":"A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis B","volume":"52","author":"Tan","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.05.004_b0130","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1172\/JCI92812","article-title":"Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation","volume":"128","author":"Rivino","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2018.05.004_b0135","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/S0168-8278(17)30463-4","article-title":"Therapeutic vaccination of chronic hepatitis B patients with ABX203 (NASVAC) to prevent relapse after stopping NUCs: contrasting timing rebound between tenofovir and entecavir","volume":"66","author":"Wedemeyer","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.05.004_b0140","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/gutjnl-2013-305707","article-title":"Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial\u2013ANRS HB02 VAC-ADN","volume":"64","author":"Fontaine","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2018.05.004_b0145","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/S0168-8278(17)30315-X","article-title":"A phase1 study evaluating anti-PD-1 treatment with or without GS-4774 in HBeAg negative chronic hepatitis B patients","volume":"66","author":"Gane","year":"2017","journal-title":"J Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827818320506?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827818320506?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:35:41Z","timestamp":1759174541000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827818320506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0168827818320506"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2018.05.004","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2018.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}